The Increasing Incidence Of PAH In the World Is Driving the Growth of the Global Pulmonary Arterial Hypertension Drug Market

 

Pulmonary Arterial Hypertension Drug Market

Pulmonary Arterial Hypertension Drug Market, by Drug Class (Endothelin Receptor Antagonists (ERAs), Phosphodiesterase-5 (PDE-5) Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators, Prostacyclin Analogue, Calcium Channel Blockers, Others), by Route of Administration (Oral, Inhaled, Intravenous, Subcutaneous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030.

The global Pulmonary Arterial Hypertension Drug Market is estimated to be valued at US$ 7,310.1 Million in 2022 and is expected to reach US$ 11,220.2 million by 2030, at a CAGR of 5.5% during the forecast period (2022–2030).

Market Overview:

Pulmonary Arterial Hypertension (PAH) is a progressive and potentially life-threatening condition that affects the pulmonary arteries, which are the blood vessels that carry blood from the heart to the lungs. In PAH, the small arteries in the lungs become narrowed, blocked, or damaged, leading to increased resistance to blood flow through the lungs.

PAH is classified as a subgroup of a broader condition called pulmonary hypertension (PH), which includes various types of high blood pressure in the pulmonary arteries. However, PAH specifically refers to pulmonary hypertension that occurs when the cause is unknown or due to certain genetic or hereditary factors.

Competitive Landscape:

Major players operating in the global Pulmonary Arterial Hypertension Drug Market include Mylan N.V., Sun Pharmaceutical Industries Ltd., Sandoz AG, Daiichi Sankyo Company, Limited, Arena Pharmaceuticals, Actelion Pharmaceuticals Ltd, Gilead Sciences, Inc., Pfizer Inc., Merck KGaA, Bayer AG, AstraZeneca, Novartis AG, GlaxoSmithKline plc., and United Therapeutics Corporation.

Key Market Drivers:

The prevalence of PAH is rising globally due to factors such as changing lifestyles, sedentary habits, and aging populations. The growing prevalence of risk factors like obesity and cardiovascular diseases has contributed to the increasing incidence of Pulmonary Arterial Hypertension Drug Market. This is expected to augment the growth of the global pulmonary arterial hypertension drug market. For instance, according to the National Institutes of Health (NIH), annually 93 cases per million individuals are diagnosed with pulmonary arterial hypertension.

Significant advancements in drug development have been witnessed in the PAH market. Several new therapies, including prostacyclin analogs, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors, have been introduced, offering improved treatment options for patients. The development of combination therapies and targeted therapies is estimated to enhance the growth of the global pulmonary arterial hypertension drug market.

Increasing healthcare expenditure, particularly in emerging economies, has positively influenced the global pulmonary arterial hypertension drug market. Growing healthcare infrastructure, rising disposable incomes, and government initiatives to improve healthcare access have led to increased spending on PAH treatment, driving market growth.

Covid-19 Impact Analysis:

The pandemic raised awareness about respiratory health, resulting in an increased focus on conditions like PAH. This awareness is expected to boost the growth of the global pulmonary arterial hypertension drug market, as governments and healthcare organizations prioritize the management of pulmonary diseases. For instance, in July 2022, Cereno Scientific stated that the first individuals had been included in the Phase II study for CS1, which is a PAH drug candidate.

Key Takeaways:

·        North America is expected to dominate the growth of the global pulmonary arterial hypertension drug market. Factors such as the high prevalence of PAH, well-established healthcare infrastructure, and early adoption of advanced therapies contribute to the region's market growth. Additionally, the presence of key market players and extensive research activities further drive the market in North America. For instance, in June 2022, Gossamer Bio, Inc. published the preclinical information supporting the efficiency of seralutinib, which can be used for treating PAH.

·        The Asia Pacific region is estimated to witness high growth in the global pulmonary arterial hypertension drug market, owing to factors such as a large population, increasing disposable incomes, and improving healthcare infrastructure. Rising awareness, the launch of generic drugs, and the presence of a vast untapped market contribute to the region's growth potential. For instance, according to Janssen Australia, more than 2000 individuals are in Australia.